8/18/2023 0 Comments Endo international plc founderThe Board believes his experience positions him to drive a broad range of growth initiatives across Endo's entire portfolio, generating better health outcomes for patients and creating value for Endo's shareholders." ![]() "Paul has spent a significant portion of his career leading and operating complex generics businesses and overseeing Par's branded business. Generic and International pharmaceutical assets," stated Roger H. "Given the continued evolution of Endo's business and Paul's impressive track record of delivering strong operating results, the Board concluded that Paul is the right leader for Endo at this juncture as we focus on execution and increasing the value of our attractive U.S. Since joining Endo, Campanelli has overseen the Company's U.S. ![]() Specifically, during his tenure, Par significantly increased total revenue, acquired JHP Pharmaceuticals and established a presence in the European generics market. ![]() While CEO of Par, Campanelli built a strong leadership team and an industry-leading generics business. Campanelli, who will also join Endo's Board of Directors, succeeds Rajiv De Silva, who has stepped down as President, CEO and a member of the Board.Ĭampanelli, 54, joined Endo in 2015 following Endo's acquisition of Par Pharmaceutical, where he had served as Chief Executive Officer since 2012. Campanelli currently serves as President of Endo's Generic and OTC drugs business, Par Pharmaceutical, which accounts for approximately 60 percent of Endo's total revenues through the first half of 2016. Campanelli President and Chief Executive Officer, effective immediately. 23, 2016 /PRNewswire/ - Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced that its Board of Directors has named Paul V. The company was founded in 1997 and is headquartered Dublin, Ireland.Brings Extensive Leadership and Operations Experience in Generics, OTC Drugs and Branded ProductsĬompany Affirms Third Quarter and Full Year 2016 Financial GuidanceĭUBLIN, Sept. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. Generic Pharmaceuticals segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health and cardiovascular disease markets, among others. Branded-Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. Branded-Specialty & Established Pharmaceuticals segment offers prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics. Generic Pharmaceuticals and International Pharmaceuticals. Branded-Specialty & Established Pharmaceuticals, U.S. The firm operates through the following segments: U.S. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. ![]() Endo International Plc operates as a pharmaceutical company.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |